| Source: |
| Type: measurement |
| Bioavailability (usually in %) absorbed by the body. |
| 8874- | MOR, | The anticarcinogenic and anticancer effects of the dietary flavonoid, morin: Current status, challenges, and future perspectives |
| - | Review, | Var, | NA |
| 8894- | MOR, | Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects |
| - | in-vivo, | Nor, | NA |
| 8889- | MOR, | Selected Flavonols in Breast and Gynecological Cancer: A Systematic Review |
| - | Review, | BC, | NA | - | Review, | Ovarian, | NA |
| 8888- | MOR, | Morin improves learning and memory in healthy adult mice |
| - | in-vivo, | AD, | NA |
| 8858- | MOR, | Mechanisms of poor oral bioavailability of flavonoid Morin in rats: From physicochemical to biopharmaceutical evaluations |
| - | in-vivo, | Nor, | NA |
| 8877- | MOR, | Enhancing bioavailability of morin via multi-particulate dosage forms: Development and pharmacokinetic insights |
| - | in-vivo, | Nor, | NA |
| 8950- | mushLions, | Absolute Bioavailability, Tissue Distribution, and Excretion of Erinacine S in Hericium erinaceus Mycelia |
| - | in-vivo, | AD, | NA |
| 8964- | mushLions, | Lion’s Mane Mushroom (Hericium erinaceus): A Neuroprotective Fungus with Antioxidant, Anti-Inflammatory, and Antimicrobial Potential—A Narrative Review |
| - | Review, | Nor, | NA | - | Review, | AD, | NA |
| 2933- | NAD, | Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns |
| - | Review, | Nor, | NA | - | NA, | AD, | NA | - | NA, | Diabetic, | NA | - | NA, | Stroke, | NA | - | NA, | LiverDam, | NA | - | NA, | Park, | NA |
| 2936- | NAD, | The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update |
| - | Review, | Nor, | NA |
| 5620- | NaHCO3, | Tumor acidity: From hallmark of cancer to target of treatment |
| - | Review, | Var, | NA |
| 1798- | NarG, | Naringenin: A potential flavonoid phytochemical for cancer therapy |
| - | Review, | Var, | NA |
| 1799- | NarG, | Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics |
| - | Review, | BC, | NA |
| 1804- | NarG, | Beneficial effects of citrus flavanones naringin and naringenin and their food sources on lipid metabolism: An update on bioavailability, pharmacokinetics, and mechanisms |
| - | Review, | Nor, | NA |
| 1805- | NarG, | Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota |
| - | in-vitro, | Ovarian, | A2780S | - | in-vivo, | NA, | NA |
| 1806- | NarG, | Naringin: Nanotechnological Strategies for Potential Pharmaceutical Applications |
| - | Review, | Var, | NA |
| 5253- | NCL, | Niclosamide: Beyond an antihelminthic drug |
| - | Review, | Var, | NA |
| 5254- | NCL, | The magic bullet: Niclosamide |
| - | Review, | Var, | NA |
| - | Trial, | Nor, | NA |
| 4643- | OLE, | HT, | Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine |
| - | Review, | Var, | NA |
| 4631- | OLE, | Evidence to Support the Anti-Cancer Effect of Olive Leaf Extract and Future Directions |
| - | Review, | Var, | NA |
| 4646- | OLEC, | Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology |
| - | Review, | Var, | NA |
| 1814- | Oxy, | Hyperbaric oxygen therapy for malignancy: a review |
| - | Review, | Var, | NA |
| 2052- | PB, | Lipid-regulating properties of butyric acid and 4-phenylbutyric acid: Molecular mechanisms and therapeutic applications |
| - | Review, | Nor, | NA |
| 2026- | PB, | Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study |
| - | Trial, | GBM, | NA |
| 2038- | PB, | A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies |
| - | Trial, | Var, | NA |
| 2045- | PB, | Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | LN-18 |
| 3247- | PBG, | Bioavailability and In Vivo Antioxidant Activity of a Standardized Polyphenol Mixture Extracted from Brown Propolis |
| - | Review, | Nor, | NA |
| 3248- | PBG, | Propolis as a promising functional ingredient: A comprehensive review on extraction, bioactive properties, bioavailability, and industrial applications |
| - | Review, | Nor, | NA |
| 3251- | PBG, | The Antioxidant and Anti-Inflammatory Effects of Flavonoids from Propolis via Nrf2 and NF-κB Pathways |
| - | Review, | AD, | NA | - | Review, | Diabetic, | NA | - | Review, | Var, | NA | - | in-vitro, | Nor, | H9c2 |
| 1668- | PBG, | Propolis: A Detailed Insight of Its Anticancer Molecular Mechanisms |
| - | Review, | Var, | NA |
| 1666- | PBG, | Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer |
| - | Review, | Var, | NA |
| 4935- | PEITC, | Phenethyl Isothiocyanate Suppresses Inhibitor of Apoptosis Family Protein Expression in Prostate Cancer Cells in Culture and In Vivo |
| - | in-vivo, | Pca, | LNCaP | - | in-vivo, | Pca, | PC3 |
| 4922- | PEITC, | Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms |
| - | Review, | Var, | NA |
| - | Trial, | Oral, | NA |
| 4920- | PEITC, | Cisplatin, | PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p |
| - | vitro+vivo, | NSCLC, | A549 |
| 4918- | PEITC, | Nutritional Sources and Anticancer Potential of Phenethyl Isothiocyanate: Molecular Mechanisms and Therapeutic Insights |
| - | Review, | Var, | NA |
| 4927- | PEITC, | Targeting ferroptosis in osteosarcoma |
| - | Review, | OS, | NA |
| 4938- | PEITC, | Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers |
| - | Trial, | Nor, | NA |
| 9028- | Phyco, | Enhancing the bioavailability and stability of phycocyanin loaded into double-layered pectin-chitosan nanocarriers |
| - | Study, | Nor, | NA |
| 9026- | Phyco, | Phycocyanin oral delivery system obtained by spray-drying with soy proteins for the treatment of inflammatory bowel diseases: in vivo evaluation |
| - | in-vivo, | IBD, | NA |
| 9024- | Phyco, | pH-activated liquid microdroplet carrier for enhanced phycocyanin oral delivery and sustained bioactivity post-digestion |
| - | Study, | Nor, | NA |
| 9030- | Phyco, | Enhancing the gastrointestinal stability of phycocyanin through modified PEGylation: Prospects for oral anticancer treatment |
| - | in-vitro, | Oral, | NA |
| 3587- | PI, | Piperine: A review of its biological effects |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
| 3595- | PI, | Black pepper and health claims: a comprehensive treatise |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 1948- | PL, | BNL, | Natural borneol serves as an adjuvant agent to promote the cellular uptake of piperlongumine for improving its antiglioma efficacy |
| - | in-vitro, | GBM, | NA |
| 2649- | PL, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 2968- | PL, | Chit, | Preparation of piperlongumine-loaded chitosan nanoparticles for safe and efficient cancer therapy |
| - | in-vitro, | GC, | AGS |
| 2967- | PL, | Piperlongumine and its derivatives against cancer: A recent update and future prospective |
| - | Review, | Var, | NA |
| 2966- | PL, | A strategy to improve the solubility and bioavailability of the insoluble drug piperlongumine through albumin nanoparticles |
| - | in-vitro, | LiverDam, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:792 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid